Analysis of Driver Gene Mutation in Early Stage Non-small Cell Lung Cancer
Molecular Metastasis in Lymph Nodes is Associated With Survival of Patients With Stage I NSCLC
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Female or male, 18 years of age or older
- Histologically or cytologically proven diagnosis of early stage NSCLC
- The lesion was completely resected by radical surgery
- Able to get tumor tissue sample
- Complete information of clinicopathological , survival, recurrence and metastasis can be obtained through follow-up
Exclusion Criteria:
- Combine with other tumor type
- The investigator judges the situation that may affect the clinical search process and results
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Driver gene mutation-positive
Screen the enrolled patients according to the admission criteria.
The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a driver gene mutation positive.
|
nonIntervention
|
|
Driver gene mutation-negative
Screen the enrolled patients according to the admission criteria.
The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a driver gene mutation negative.
|
nonIntervention
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Driver gene mutation frequency of early stage NSCLC
Time Frame: 2019
|
Observe the driver gene mutation frequency in regional lymph nodes of early stage non-small cell lung cancer
|
2019
|
|
Correlation of Clinicopathological characteristics and driver gene mutation in regional lymph nodes of early stage NSCLC
Time Frame: 2019
|
Analyze the correlation between driver gene mutation and clinicopathological features in regional lymph nodes of early stage NSCLC
|
2019
|
|
Correlation between driver gene mutation and survival prognosis in regional lymph nodes of early stage NSCLC
Time Frame: 2019
|
Observe the correlation between driver gene mutation and survival prognosis in regional lymph nodes of early stage NSCLC
|
2019
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- LN-OMs
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.